These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26237261)

  • 1. Effectiveness of Proadrenomedullin Enhanced CURB65 Score Algorithm in Patients with Community-Acquired Pneumonia in "Real Life", an Observational Quality Control Survey.
    Widmer D; Drozdov D; Rüegger K; Litke A; Arici B; Regez K; Guglielmetti M; Schild U; Conca A; Schäfer P; Kouegbe RB; Reutlinger B; Blum C; Schuetz P; Irani S; Huber A; Bürgi U; Müller B; Albrich WC
    J Clin Med; 2014 Mar; 3(1):267-79. PubMed ID: 26237261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm.
    Albrich WC; Dusemund F; Rüegger K; Christ-Crain M; Zimmerli W; Bregenzer T; Irani S; Buergi U; Reutlinger B; Mueller B; Schuetz P
    BMC Infect Dis; 2011 May; 11():112. PubMed ID: 21539743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections.
    Albrich WC; Rüegger K; Dusemund F; Bossart R; Regez K; Schild U; Conca A; Schuetz P; Sigrist T; Huber A; Reutlinger B; Müller B
    Swiss Med Wkly; 2011; 141():w13237. PubMed ID: 21805408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
    PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections.
    Schuetz P; Wolbers M; Christ-Crain M; Thomann R; Falconnier C; Widmer I; Neidert S; Fricker T; Blum C; Schild U; Morgenthaler NG; Schoenenberger R; Henzen C; Bregenzer T; Hoess C; Krause M; Bucher HC; Zimmerli W; Mueller B;
    Crit Care; 2010; 14(3):R106. PubMed ID: 20529344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department.
    Liu B; Yin Q; Chen YX; Zhao YZ; Li CS
    Respir Med; 2014 Aug; 108(8):1204-13. PubMed ID: 24931899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia.
    Schuetz P; Litke A; Albrich WC; Mueller B
    Curr Opin Infect Dis; 2013 Apr; 26(2):159-67. PubMed ID: 23434895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.
    Barlow G; Nathwani D; Davey P
    Thorax; 2007 Mar; 62(3):253-9. PubMed ID: 16928720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of prediction rules of mortality risk for CAP in a developing country.
    Zuberi FF; Khan JA
    Int J Tuberc Lung Dis; 2008 Apr; 12(4):447-52. PubMed ID: 18371273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
    Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
    Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of CURB65-guided antibiotic therapy in community-acquired pneumonia.
    Chalmers JD; Singanayagam A; Akram AR; Choudhury G; Mandal P; Hill AT
    J Antimicrob Chemother; 2011 Feb; 66(2):416-23. PubMed ID: 21081545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
    Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
    Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
    Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
    Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The change in age distribution of CAP population in Korea with an estimation of clinical implications of increasing age threshold of current CURB65 and CRB65 scoring system.
    Kim B; Kim J; Jo YH; Lee JH; Hwang JE
    PLoS One; 2019; 14(8):e0219367. PubMed ID: 31415581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.